CB Insights
Technology Market Intelligence
Technology Market Intelligence
Public list: Smart Money VCs (6326) Pharma Startups (6570) Cancer Therapeutics (1180) Rare Diseases (230)
Millendo Therapeutics, previously known as Atterocor, is a drug development company focused on a treatment for adrenal cancer. The company seeks to develop adrenal-targeting therapy for the treatment of adrenocortical carcinoma (ACC) patients.
Company (IPO / Went public)
Phone: 734-845-9000
301 North Main Street
Suite 100
Ann Arbor, 48104
Michigan, United States
| Per Week | Per Month | Per 6 Months | Per Year | |
|---|---|---|---|---|
| Rank | Login to see details | |||
| Page Views Per Million | Login to see details | |||
| Page Views Per User | Login to see details | |||
| Reach Per Million | Login to see details | |||
| Title | Application Date | Patent Date | Status (Patent / Application) |
|---|---|---|---|
| Solid drug form of n-(2,6-bis(1-methylethyl)phenyl)-n'-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride and compositions, methods and kits related thereto | Dec 06, 2016 | Aug 28, 2018 | Patent |
| Compounds and methods for treating aberrant adrenocortical cell disorders | Jun 01, 2016 | Jan 30, 2018 | Patent |
| Solid drug form of n-(2,6-bis(1-methylethyl)phenyl)-n'-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride and compositions, methods and kits related thereto | Sep 25, 2015 | Jan 17, 2017 | Patent |
| Compounds and methods for treating aberrant adrenocortical cell disorders | Jul 13, 2015 | Sep 20, 2016 | Patent |
| Solid drug form of n-(2,6-bis(1-methylethyl)phenyl)-n'-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride and compositions, methods and kits related thereto | Sep 20, 2019 | Application |
